| 000 | 01765 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250514215709.0 | ||
| 264 | 0 | _c20051026 | |
| 008 | 200510s 0 0 eng d | ||
| 022 | _a1471-2458 | ||
| 024 | 7 |
_a10.1186/1471-2458-5-14 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFarah, Mohamed Guled | |
| 245 | 0 | 0 |
_aTreatment outcome of new culture positive pulmonary tuberculosis in Norway. _h[electronic resource] |
| 260 |
_bBMC public health _cFeb 2005 |
||
| 300 |
_a14 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEthambutol _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aIsoniazid _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 |
_aNorway _xepidemiology |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 |
_aPyrazinamide _xtherapeutic use |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdiagnosis |
| 700 | 1 | _aTverdal, Aage | |
| 700 | 1 | _aSteen, Tore W | |
| 700 | 1 | _aHeldal, Einar | |
| 700 | 1 | _aBrantsaeter, Arne B | |
| 700 | 1 | _aBjune, Gunnar | |
| 773 | 0 |
_tBMC public health _gvol. 5 _gp. 14 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2458-5-14 _zAvailable from publisher's website |
| 999 |
_c15375057 _d15375057 |
||